The FDA has initiated a nationwide recall of some levothyroxine sodium tablets distributed by Major Pharmaceuticals after finding the medicine was subpotent. The recall covers only certain lots of the thyroid drug, which is used to treat hypothyroidism and goiter, among other conditions.
That makes the notice relevant now for anyone who takes levothyroxine and wants to know whether the tablets in a medicine cabinet are part of the action. The affected product was sold in 10-count blister packs, either as individual packs or bundled into cartons containing 10 blister packs, so patients are being asked to look closely at the packaging they have on hand.
Levothyroxine is a medication where even a small shortfall can matter, because subpotent means the tablets deliver less medicine than intended. The FDA classified the recall as Class II, its designation for products that may cause temporary, reversible health effects, which is a restrained label for a drug that people often take every day to keep thyroid levels steady.
The gap for readers is straightforward: the recall notice does not include the specific lot numbers and expiration dates in the available information, so people cannot confirm whether their tablets are affected just by the drug name alone. The practical step is to check the package carefully and contact a doctor or pharmacist for guidance if there is any match or doubt.
Patients should not stop taking levothyroxine on their own unless a healthcare provider tells them to do so. Suddenly stopping a drug can cause ill effects in some cases, and for a medicine used to manage hypothyroidism and goiter, that warning matters as much as the recall itself. A breakdown of the broader action is available in Levothyroxine Recall 2026: FDA flags subpotent tablets in nationwide action.
